United States Food and Drug Administration approved Johnson & Johnson (NYSE:JNJ), one of the world’s biggest health-care conglomerate, medicine to treat a form of resistant tuberculosis that is uncommon in the United States but rising worldwide.
Johnson & Johnson’s drug, Sirturo, will treat patients with multidrug resistant tuberculosis, a probably fatal disease that affects around 630,000 people globally who cannot be cured with existing therapies alone. Tuberculosis is a bacterial infection that mainly involves the lungs.
Sirturo is not projected to be a big moneymaker for Johnson & Johnson as the disease is prevalent in poorer countries not capable to afford high prices for the treatment.
Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Mylan Inc. (NASDAQ:MYL) rose +1.97% to settle at $27.45, Watson Pharmaceuticals, Inc. (NYSE:WPI) moved down -3.41% to end at $86.00 while GlaxoSmithKline plc (ADR) (NYSE:GSK) jumped +0.56% to finish at $43.47 on Monday.
Johnson & Johnson (NYSE:JNJ) last session’s volume of 12.77 million shares was higher than its average volume of 11.11 million shares. The stock after opening at $69.24 hit high price of $70.11 and then closed at $70.10 by scoring +0.89%.
JNJ generated revenue of $65.92 billion in the previous twelve months and earned $8.50 billion. The Company showed a positive 12.39% in the net profit margin as well as in its operating margin which remained at 16.68%. Company’s annual sales growth for the past five years was 4.05%.
The JNJ’s past twelve months’ price to sales ratio was 2.95 and price to cash ratio remained 9.83. As far as the returns are concerned, JNJ’s return on equity was recorded as 13.58% and return on investment increased 8.82% while its return on asset stayed at 7.08%.
The stock showed weekly downbeat performance of -0.24% which was maintained for the month at 1.27%. Likewise the positive performance for the quarter was recorded as 2.47% and for the year was 11.08% while the YTD performance remained at 10.85%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL